Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VIP236 (Q3W)
VIP236 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation of VIP236 (Q3W) | EXPERIMENTAL | Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer. Dosing occurs on D1 of each 21-day cycle |
| Dose Escalation of VIP236 (Q2W) | EXPERIMENTAL | Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer. Dosing occurs on D1 and D15 of each 28-day cycle. |
| Name | Type | Description |
|---|---|---|
| VIP236 (Q3W) | DRUG | VIP236 will be administered by IV infusion once every 3 weeks, for a 21-day cycle. |
| VIP236 (Q2W) | DRUG | VIP236 will be administered by IV infusion once every 2 weeks, for a 28-day cycle. |
Inclusion Criteria: * Adult patients aged \>/=18 years, able to provide informed consent and willing to comply with all study procedures. * Histologically confirmed advanced or metastatic solid tumors that are relapsed or refractory to standard of care. Subjects must have exhausted all available st...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
VIP236 is an investigational small molecule being studied for the treatment of advanced solid tumors and other neoplasms. It is being developed by Vincerx Pharma, Inc. as an oncology therapy. The compound has been evaluated in a Phase 1 dose escalation study in patients with advanced cancer, but it is not approved for any indication.
VIP236 is being developed by Vincerx Pharma, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol VINC. Vincerx is responsible for the clinical development of VIP236, including the Phase 1 trial conducted in the United States and Australia.
VIP236 is in Phase 1 clinical development. A single Phase 1 dose escalation study has been completed, enrolling 29 patients with advanced cancer. The trial was not randomized and did not use a double-blind design. VIP236 remains investigational and has not been approved by the FDA for any use.
VIP236 has been evaluated in one clinical trial: NCT05712889, titled "Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer." This completed Phase 1 trial enrolled 29 patients with neoplasms across sites in the United States and Australia. It was a controlled, non-randomized, open-label study in adults aged 18 years and older.
Yes, VIP236 (Q3W) refers to the same investigational compound as VIP236. The Q3W designation indicates once every three weeks dosing, which was the schedule used in the Phase 1 clinical trial. Both names refer to the small molecule oncology candidate developed by Vincerx Pharma.